Gallbladder cancer rates have been stable or declining for most Americans over the last two decades, but cases have steadily risen among Blacks, with growing numbers not being diagnosed until later stages, according to a study scheduled for presentation at Digestive Disease Week 2024.
MASCT by Hengrui Yuanzheng Biotechnology for Metastatic Colorectal Cancer: Likelihood of Approval
MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Metastatic Colorectal Cancer.